Condition: Metastatic Colorectal Cancer · Sponsor: Centre Hospitalier Universitaire de Besancon
The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic colorectal cancer by assessing progression-free survival.
This description comes directly from the study's public registry record.
Angélique VIENOT, Dr · +33 370632278 · a3vienot@chu-besancon.fr
Christophe BORG, Pr · xtoph.borg@gmail.com
Always discuss trial participation with your own doctor first.
| CHU d'Auxerre | Auxerre, France | Recruiting |
| Centre Hospitalier Universitaire de Besançon | Besançon, France | Recruiting |
| CH de Colmar | Colmar, France | Recruiting |
| Centre Georges-François Leclerc (CGFL) | Dijon, France | Recruiting |
| Hôpital Robert Schuman | Metz, France | Recruiting |
| Hôpital Nord Franche-Comté | Montbéliard, France | Recruiting |
| CHU de Montpellier | Montpellier, France | Recruiting |
| CHU de Reims - Hôpital Robert Debré | Reims, France | Recruiting |
| Clinique Privée de Strasbourg | Strasbourg, France | Not Yet Recruiting |
| ICANS | Strasbourg, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06425133